Verrucous Carcinoma Market Research Report – Forecast to 2027

Verrucous Carcinoma Market Research Report, by Diagnosis (Biopsy, Endoscopy, Imaging Tests), Treatment (Radiation Therapy, Chemotherapy), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers) – Global Forecast Till 2027

ID: MRFR/LS/4906-HCR | | Region: Global | 90 pages

Verrucous Carcinoma Market Scenario


Verrucous carcinoma (VC) is a rare type of squamous cell carcinoma and is categorized under head and neck cancer.  It is mainly caused due to the chewing of tobacco or snuffing it orally. It is also called as snuff dipper's cancer. Verrucous carcinoma most commonly occurs at oral sites but is also observed in head and neck genital locations. It is mainly observed in males than in females and is found in the age group of 50 to 80 years. The key factor responsible for influencing this market is the increasing prevalence of oral cancer. It may also be caused due to lifestyle factors such as smoking tobacco or marijuana, alcohol consumption, and others. Other key factors such as a change to sedentary lifestyle, growing consumption of alcohol, increasing tobacco users of dip, snuff, increase in smoking, rising family history of cancer prevalence, and increasing prevalence of sexually transmitted diseases by human papillomavirus are contributing towards the growth of the market. According to the World Health Organization in 2015, globally 1.1 billion people smoked tobacco. This is expected to provide favorable backgrounds for market growth during the forecast period.


However, factors such as the high cost of surgical procedures, expensive chemotherapy treatments, and side effects associated with treatments are expected to restrict the market growth during the forecast period.


Segmentation


The verrucous carcinoma market is segmented on the basis of diagnosis, treatment, and end-user. The verrucous carcinoma market, by diagnosis, is categorized into biopsy, endoscopy, and imaging tests. Imaging tests are categorized into computerized tomography scans, magnetic resonance imaging, and positron emission tomography scans. On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, and targeted drug therapy. The surgery category consists of surgical excision and mohs micrographic surgery. Chemotherapy consists of bleomycin, 5-fluorouracil, cisplatin, methotrexate, and others. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.


On the basis of region, the verrucous carcinoma market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the verrucous carcinoma market are Bristol-Myers Squibb Company (US) Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company. (US), F. Hoffmann-La Roche Ltd (Europe), Merck & Co., Inc. (US), Novartis AG (Europe), Pfizer Inc. (US), and others.


Regional Market Summary


Verrucous Carcinoma Market Share (%), by Region, 2017


Verrucous Carcinoma Market Share


Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health


It is estimated that North America dominated the verrucous carcinoma market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society in August 2018 granted USD 15,866,878 for head and neck cancer research projects. This influences the market growth in this region


Europe stood second largest in the verrucous carcinoma market owing to the increasing use of tobacco According to the World Health Organization’s Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of tobacco smoking among adults that is 28% of adults in Europe are engaged in tobacco smoking. Such a high prevalence of smoking in this region facilitates the market growth.


Asia-Pacific was projected to be the fastest growing region for the verrucous carcinoma market in 2017. The market is expected to witness growth owing to the rising prevalence of oral cancer, changing lifestyle, and increasing tobacco use within the population. The Center for Cancer Control and Information Services estimated 15,600 cases of oral cavity and pharynx cancer in 2017 in Japan. Such a high incidence of oral cancer favors the market growth in this region.


The Middle East and Africa holds the least share in the verrucous carcinoma market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.


Market Segmentation and Key Market Players


Verrucous Carcinoma Market, by Diagnosis



  • Biopsy

  • Endoscopy

  • Imaging tests

  • Computerized Tomography (CT) scans

  • Magnetic Resonance Imaging (MRI)

  • Positron Emission Tomography (PET) scans


Verrucous Carcinoma Market, by Treatment



  • Surgery


    • Surgical excision

    • Mohs Micrographic Surgery (MMS)

    • Cryosurgery


  • Radiation therapy

  • Chemotherapy


    • Bleomycin

    • 5-fluorouracil

    • Cisplatin

    • Methotrexate


  • Targeted drug therapy


Verrucous Carcinoma Market, by End-Users



  • Hospitals and clinics

  • Ambulatory surgical centers

  • Diagnostic centers

  • Research centers

  • Others


Verrucous Carcinoma Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


North America is expected to lead the Verrucous Carcinoma Market.

Different end use industries of verrucous carcinoma include diagnostic centers, ambulatory surgical centers, hospitals and clinics, and others.

Rising prevalence of oral cancer and increasing alcohol consumption are adding market growth.

Side effects and high treatment cost may limit market growth.

Different strategies used by industry players to create a dominance in the Verrucous Carcinoma Market include mergers, partnerships, strategic alliances, and product launches.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Verrucous Carcinoma Market, by Diagnosis

6.1 Introduction

6.2 Biopsy

6.3 Endoscopy

6.4 Imaging tests

6.4.1 Computerized Tomography (CT) scans

6.4.2 Magnetic Resonance Imaging (MRI)

6.4.3 Positron Emission Tomography (PET) scans

Chapter 7. Global Verrucous Carcinoma Market, by Treatment

7.1 Introduction

7.2 Surgery

7.2.1 Surgical excision

7.2.2 Mohs Micrographic Surgery (MMS)

7.2.5 Cryosurgery

7.3 Radiation therapy

7.4 Chemotherapy

7.3.1 Bleomycin

7.3.2 5-fluorouracil

7.3.3 Cisplatin

7.3.4 Methotrexate

7.3.5 Others

7.5 Targeted drug therapy

Chapter 8. Global Verrucous Carcinoma Market, by End-Users

8.1 Introduction

8.2 Hospitals and clinics

8.3 Ambulatory Surgical Centers

8.4 Diagnostic Centers

8.5 Research centers

8.6 Others

Chapter 9. Global Verrucous Carcinoma Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Bristol-Myers Squibb Company

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 Qilu Pharmaceutical Co., Ltd.

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Teva Pharmaceutical Industries Ltd.

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Eli Lilly and Company

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 F. Hoffmann-La Roche Ltd

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Merck & Co., Inc

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Novartis AG

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 PFIZER INC

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.12 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Verrucous Carcinoma Market Industry Synopsis, 2020-2027

Table 2 Global Verrucous Carcinoma Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Verrucous Carcinoma Market, by Region, 2020-2027, (USD Million)

Table 4 Global Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 6 Global Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 7 North America: Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 8 North America: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 9 North America: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 10 US: Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 11 US: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 12 US: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 13 Canada: Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 15 Canada: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 16 South America: Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 17 South America: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 18 South America: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 19 Europe: Verrucous Carcinoma Market, Diagnosis, 2020-2027, (USD Million)

Table 20 Europe: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 21 Europe: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 22 Western Europe: Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 25 Eastern Europe: Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 28 Asia-Pacific: Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia-Pacific: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 30 Asia-Pacific: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

Table 31 Middle East & Africa: Verrucous Carcinoma Market, by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa: Verrucous Carcinoma Market, by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa: Verrucous Carcinoma Market, by End-User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Verrucous Carcinoma Market

Figure 3 Market Dynamics for the Global Verrucous Carcinoma Market

Figure 4 Global Verrucous Carcinoma Market Share, by diagnosis 2020

Figure 6 Global Verrucous Carcinoma Market Share, by treatment, 2020

Figure 6 Global Verrucous Carcinoma Market Share, by End-User, 2020

Figure 7 Global Verrucous Carcinoma Market Share, by Region, 2020

Figure 8 North America Verrucous Carcinoma Market Share, by Country, 2020

Figure 9 Europe Prescribed Health Apps Share, by Country, 2020

Figure 10 Asia-Pacific Verrucous Carcinoma Market Share, by Country, 2020

Figure 11 Middle East & Africa Verrucous Carcinoma Market Share, by Country, 2020

Figure 12 Global Verrucous Carcinoma Market: Company Share Analysis, 2020 (%)

Figure 13 Bristol-Myers Squibb Company: Key Financials

Figure 14 Bristol-Myers Squibb Company: Segmental Revenue

Figure 15 Bristol-Myers Squibb Company: Geographical Revenue

Figure 16 Qilu Pharmaceutical Co., Ltd.: Key Financials

Figure 17 Qilu Pharmaceutical Co., Ltd.: Segmental Revenue

Figure 18 Qilu Pharmaceutical Co., Ltd.: Geographical Revenue

Figure 19 Teva Pharmaceutical Industries Ltd. : Key Financials

Figure 20 Teva Pharmaceutical Industries Ltd. : Segmental Revenue

Figure 21 Teva Pharmaceutical Industries Ltd. : Geographical Revenue

Figure 22 Eli Lilly and Company: Key Financials

Figure 23 Eli Lilly and Company: Segmental Revenue

Figure 24 Eli Lilly and Company: Geographical Revenue

Figure 25 Merck & Co., Inc: Key Financials

Figure 26 Merck & Co., Inc: Segmental Revenue

Figure 27 Merck & Co., Inc: Geographical Revenue

Figure 28 Novartis AG: Key Financials

Figure 29 Novartis AG: Segmental Revenue

Figure 30 Novartis AG: Geographical Revenue

Figure 31 Pfizer Inc: Key Financials

Figure 32 Pfizer Inc: Segmental Revenue

Figure 33 Pfizer Inc: Geographical Revenue